Targeting PIM Kinase With PD1 Inhibition Improves Immunotherapeutic Anti-Tumor T Cell Response

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-0706
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

CD38-NAD + Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response

Cell Metabolism
Cell BiologyMolecular BiologyPhysiology
2018English

Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer

Frontiers in Immunology
AllergyImmunology
2018English

Targeting Tumor-Intrinsic Hexosamine Biosynthesis Sensitizes Pancreatic Cancer to Anti-Pd1 Therapy

Journal of Clinical Investigation
Medicine
2019English

YAP Attenuates CD8 T Cell-Mediated Anti-Tumor Response

Frontiers in Immunology
AllergyImmunology
2020English

Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-Tumor Immunity

Frontiers in Immunology
AllergyImmunology
2018English

Targeting Transcriptional Regulators of CD8+ T Cell Dysfunction to Boost Anti-Tumor Immunity

Vaccines
Drug DiscoveryInfectious DiseasesImmunologyPharmacology
2015English

Response to Anti-Pd1 Therapy With Nivolumab in Metastatic Sarcomas

Clinical Sarcoma Research
Oncology
2016English

T Cell Costimulatory Molecules in Anti-Viral Immunity: Potential Role in Immunotherapeutic Vaccines

Canadian Journal of Infectious Diseases
2003English

Pim Protein Kinase-Levels Correlate With Prostate Tumor Growth and Chemo-Resistance - Potential Mechanism of PIM Action

2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy